Mostrar el registro sencillo del ítem
dc.contributor.author
Wilson, Thomas J.
dc.contributor.author
Candolfi, Marianela
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Assi, Hikmat
dc.contributor.author
Moreno Ayala, Mariela Alejandra
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Mineharu,Yohei
dc.contributor.author
Hervey-Jumper, Shawn L.
dc.contributor.author
Lowenstein, Pedro R.
dc.contributor.author
Castro, Maria Graciela
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.other
Hayat, M. A.
dc.date.available
2020-10-21T20:19:45Z
dc.date.issued
2014
dc.identifier.citation
Wilson, Thomas J.; Candolfi, Marianela; Assi, Hikmat; Moreno Ayala, Mariela Alejandra; Mineharu,Yohei; et al.; Immunotherapies for brain cancer: from preclinical models to human trials; Springer; 13; 2014
dc.identifier.isbn
978-94-007-7601-2
dc.identifier.uri
http://hdl.handle.net/11336/116278
dc.description.abstract
Glioblastoma Multiforme (GBM) is the most common and aggressive primary brain tumor. Every year ~22,000 patients are diagnosed with GBM in the US, and less than 5% survive 5 years post-diagnosis. Thus, novel therapeutic approaches are urgently needed to improve the outcome in these patients. Immunotherapy has the potential of stimulating the immune system to eliminate GBM cells that might have spread throughout the brain. Here we will discuss the latest advances in preclinical immunotherapy for glioma, which involve the local delivery of pro-inflammatory cytokines, such as Flt3L, Type I IFNs, IL-2, IL-4, and IL-12 using gene therapy vectors and neural stem cells, or the blockade of immune-suppressive mediators such as TGF-beta, FasL and phosphorylated STAT3. Novel immunotherapeutic approaches have also been assessed in clinical trials implemented in GBM patients. These involve the systemic or local adoptive transfer of autologous immune cells activated ex vivo back into the patient, and the administration of dendritic cell vaccines loaded with tumor peptides or cells, which induce active immunity against GBM. Preclinical and clinical findings so far indicate that immunotherapy improves anti-tumor immunity in preclinical GBM models and patients, which makes it a valuable adjuvant in the treatment of GBM.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Springer
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
GLIOBLASTOMA
dc.subject
IMMUNOTHERAPY
dc.subject
GENE THERAPY
dc.subject.classification
Otras Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Immunotherapies for brain cancer: from preclinical models to human trials
dc.type
info:eu-repo/semantics/publishedVersion
dc.type
info:eu-repo/semantics/bookPart
dc.type
info:ar-repo/semantics/parte de libro
dc.date.updated
2020-04-24T13:49:40Z
dc.journal.volume
13
dc.journal.pais
Países Bajos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: Wilson, Thomas J.. University of Michigan; Estados Unidos
dc.description.fil
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
dc.description.fil
Fil: Assi, Hikmat. University of Michigan; Estados Unidos
dc.description.fil
Fil: Moreno Ayala, Mariela Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
dc.description.fil
Fil: Mineharu,Yohei. University of Michigan; Estados Unidos
dc.description.fil
Fil: Hervey-Jumper, Shawn L.. University of Michigan; Estados Unidos
dc.description.fil
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
dc.description.fil
Fil: Castro, Maria Graciela. University of Michigan; Estados Unidos
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/chapter/10.1007/978-94-007-7602-9_25
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/978-94-007-7602-9_25
dc.source.titulo
Tumors of the Central Nervous System
Archivos asociados